Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biomarker
|
| gptkbp:abbreviation |
gptkb:TMB
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:associatedWith |
immunotherapy response
|
| gptkbp:canVaryBy |
tumor subtype
cancer type |
| gptkbp:FDAApprovalFor |
pembrolizumab in solid tumors
|
| gptkbp:higherTMBAssociatedWith |
better response to immune checkpoint inhibitors
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tumor Mutational Burden
|
| gptkbp:measures |
next-generation sequencing
whole exome sequencing mutations per megabase |
| gptkbp:regulates |
tumor immunogenicity
|
| gptkbp:relatedTo |
microsatellite instability
neoantigen load |
| gptkbp:standardizedBy |
FoundationOne CDx assay
MSK-IMPACT assay |
| gptkbp:studiedIn |
gptkb:neuroblastoma
gptkb:Wilms_tumor gptkb:carcinoid_tumor gptkb:cancer gptkb:medulloblastoma gptkb:endometrial_cancer gptkb:rhabdomyosarcoma gptkb:retinoblastoma gptkb:pheochromocytoma gptkb:Ewing_sarcoma gptkb:chordoma colorectal cancer esophageal cancer leukemia liver cancer melanoma mesothelioma multiple myeloma pancreatic cancer prostate cancer testicular cancer bladder cancer adrenocortical carcinoma head and neck cancer osteosarcoma paraganglioma gastric cancer glioma renal cell carcinoma malignant peripheral nerve sheath tumor germ cell tumor |
| gptkbp:thresholdForHighTMB |
10 mutations per megabase
|
| gptkbp:usedAs |
prognostic biomarker
predictive biomarker |
| gptkbp:usedIn |
cancer research
oncology |
| gptkbp:bfsParent |
gptkb:TMB
|
| gptkbp:bfsLayer |
7
|